Noile-Immune Biotech (TSE:4893) Capex-to-Revenue : 0.00 (As of Mar. 2024)

Noile-Immune Biotech Capex-to-Revenue Chart

Noile-Immune Biotech Quarterly Data
	Dec20	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Capex-to-Revenue	Get a 7-Day Free Trial				-	-	-	-	-

Competitive Comparison of Noile-Immune Biotech's Capex-to-Revenue

For the Biotechnology subindustry, Noile-Immune Biotech's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Noile-Immune Biotech's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Noile-Immune Biotech's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Noile-Immune Biotech's Capex-to-Revenue falls into.

Noile-Immune Biotech Capex-to-Revenue Calculation

Noile-Immune Biotech's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Noile-Immune Biotech's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Noile-Immune Biotech  (TSE:4893) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Noile-Immune Biotech Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Noile-Immune Biotech's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Noile-Immune Biotech (TSE:4893) Business Description